ICONOVO AB PUBLISHES THE ANNUAL REPORT 2023 IN ENGLISH
The abbreviated annual report 2023 in English is attached to this press release and is now available on the company's website, www.iconovo.se.
The abbreviated annual report 2023 in English is attached to this press release and is now available on the company's website, www.iconovo.se.
About Iconovo
Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Carnegie Investment Bank AB (publ).